Q3 2019 Earnings Forecast for Cara Therapeutics Inc (CARA) Issued By Jefferies Financial Group

Cara Therapeutics Inc (NASDAQ:CARA) – Jefferies Financial Group issued their Q3 2019 earnings per share estimates for shares of Cara Therapeutics in a research report issued to clients and investors on Wednesday, March 13th. Jefferies Financial Group analyst C. Howerton forecasts that the biopharmaceutical company will post earnings of ($0.55) per share for the quarter. Jefferies Financial Group currently has a “Buy” rating and a $22.00 target price on the stock. Jefferies Financial Group also issued estimates for Cara Therapeutics’ Q4 2019 earnings at ($0.55) EPS.

CARA has been the topic of a number of other research reports. BidaskClub upgraded Cara Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Tuesday. Janney Montgomery Scott assumed coverage on Cara Therapeutics in a research note on Thursday, December 20th. They issued a “buy” rating and a $13.36 target price on the stock. Zacks Investment Research downgraded Cara Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, January 21st. HC Wainwright set a $30.00 target price on Cara Therapeutics and gave the company a “buy” rating in a research note on Thursday, December 20th. Finally, Bank of America assumed coverage on Cara Therapeutics in a research note on Tuesday, January 15th. They issued a “neutral” rating and a $19.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. Cara Therapeutics has an average rating of “Buy” and a consensus price target of $24.03.

Shares of NASDAQ CARA opened at $18.37 on Thursday. Cara Therapeutics has a one year low of $11.46 and a one year high of $24.30. The stock has a market capitalization of $684.83 million, a price-to-earnings ratio of -8.92 and a beta of 2.68.

Cara Therapeutics (NASDAQ:CARA) last issued its earnings results on Tuesday, March 12th. The biopharmaceutical company reported ($0.52) EPS for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.07. The firm had revenue of $5.53 million during the quarter, compared to analysts’ expectations of $3.35 million.

Several institutional investors and hedge funds have recently added to or reduced their stakes in CARA. ETF Managers Group LLC bought a new stake in shares of Cara Therapeutics during the 4th quarter worth about $7,624,000. BlackRock Inc. boosted its stake in shares of Cara Therapeutics by 23.1% during the 3rd quarter. BlackRock Inc. now owns 2,758,118 shares of the biopharmaceutical company’s stock worth $66,055,000 after acquiring an additional 516,870 shares in the last quarter. Vanguard Group Inc boosted its stake in shares of Cara Therapeutics by 24.5% during the 3rd quarter. Vanguard Group Inc now owns 1,551,344 shares of the biopharmaceutical company’s stock worth $37,155,000 after acquiring an additional 305,020 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Cara Therapeutics by 24.5% during the 3rd quarter. Vanguard Group Inc. now owns 1,551,344 shares of the biopharmaceutical company’s stock worth $37,155,000 after acquiring an additional 305,020 shares in the last quarter. Finally, Nexthera Capital LP boosted its stake in shares of Cara Therapeutics by 69.2% during the 3rd quarter. Nexthera Capital LP now owns 737,303 shares of the biopharmaceutical company’s stock worth $17,658,000 after acquiring an additional 301,503 shares in the last quarter. Institutional investors own 61.72% of the company’s stock.

In other news, CEO Derek T. Chalmers sold 15,825 shares of the company’s stock in a transaction dated Friday, December 28th. The stock was sold at an average price of $12.53, for a total transaction of $198,287.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Scott Terrillion sold 3,100 shares of the company’s stock in a transaction dated Friday, December 28th. The stock was sold at an average price of $12.51, for a total value of $38,781.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 144,983 shares of company stock valued at $2,178,154. 6.70% of the stock is currently owned by corporate insiders.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.

Featured Story: Call Option

Earnings History and Estimates for Cara Therapeutics (NASDAQ:CARA)

Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.